Johnson & Johnson Aktie News

Johnson & Johnson on ​Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit ‌of "hundreds of millions of dollars" from the drug pricing deal it signed with the Trump administration earlier this month.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical inn...

The healthcare company's forecast for 2026 tops Wall Street's expectations.

Am Mittwoch werden Anleger ganz besonders auf die Zahlen bei Charles Schwab, Halliburton, Johnson & Johnson und Travelers schauen.

It is possible to build wealth through dividend investing. While it isn't guaranteed that your investment will grow, you'll continue to enjoy passive income as long as you hold the stock.

Healthcare may be entering early mean reversion, but much of Johnson & Johnson's valuation recovery has already occurred. Post-Kenvue, JNJ is a higher-growth, less dividend-centric business, changing how income investors should evaluate the stock. Free cash flow momentum has improved, supporting reinvestment and potential multiple expansion if execution continues.

Johnson & Johnson is downgraded to Hold, as valuation is now stretched after a 50% 12-month rally. JNJ trades above 21x forward EPS, exceeding its long-term average and offering a limited margin of safety despite strong fundamentals. Q3 results were robust, with $24B in revenue and a 69.6% gross margin; management raised FY25 sales guidance and maintains an operational EPS outlook.

AbbVie has increased its dividend by 333% since 2013. Coca-Cola is a Dividend King that still has plenty of growth potential.